Nagisa Y, Mihara T, Hamajo K, Imamoto T, Kandori H, Oda E, Chatani F, Nagaoka A
Pharmaceutical Research Laboratories I, Takeda Chemical Industries, Ltd. Co., Osaka, Japan.
Nihon Yakurigaku Zasshi. 1995 Nov;106(5):327-37. doi: 10.1254/fpj.106.327.
We investigated the effects of the combination of idebenone, an energy metabolism enhancer, and manidipine 2HCl, a dihydropyridine-derivative calcium antagonist, on neurological deficits and histological changes in the brain and kidneys of stroke-prone spontaneously hypertensive rats (SHRSP) with cerebrovascular lesions (stroke). The SHRSP were kept on a 1% NaCl solution as their drinking water to synchronize the onset of stroke. After the onset of stroke symptoms, the salt solution was replaced with tap water. On the day following the onset of stroke, idebenone (50 mg/kg), manidipine 2HCl (2 mg/kg) or a combination of idebenone (50 mg/kg) and manidipine 2HCl (2 mg/kg) was administered orally once a day for 3 weeks. In the combination group and manidipine 2HCl-treated group, the neurological deficits after the onset of stroke were ameliorated during the entire experimentalperiod. Especially, the combination significantly decreased the number of days with severe neurological deficits as compared to the control group. The combination and manidipine 2HCl significantly recovered the decrease in body weight and ameliorated the increase of brain weight, which was mainly caused by edema, significantly as compared to the control group. Manidipine 2HCl ameliorated the histological changes in the brain. In the combination group, the histological changes in both the brain and the kidneys were ameliorated. In conclusion, the combination of idebenone and manidipine 2HCl significantly ameliorated the neurological deficits and the histological changes in the brain and the kidney of SHRSP with stroke as compared to each individual treatment. We concluded that manidipine 2HCl enhances the therapeutic effect of idebenone in the treatment of cerebrovascular diseases.
我们研究了艾地苯醌(一种能量代谢增强剂)与盐酸马尼地平(一种二氢吡啶衍生物钙拮抗剂)联合使用对易发生脑卒中的自发性高血压大鼠(SHRSP)脑部和肾脏神经功能缺损及组织学变化的影响。这些SHRSP饮用1%的氯化钠溶液作为饮用水,以同步脑卒中的发病时间。脑卒中症状出现后,将盐溶液换成自来水。在脑卒中发病后的第二天,每天口服一次艾地苯醌(50mg/kg)、盐酸马尼地平(2mg/kg)或艾地苯醌(50mg/kg)与盐酸马尼地平(2mg/kg)的组合,持续3周。在联合用药组和盐酸马尼地平治疗组中,脑卒中发病后的神经功能缺损在整个实验期间均得到改善。特别是,与对照组相比,联合用药组严重神经功能缺损的天数显著减少。与对照组相比,联合用药组和盐酸马尼地平组显著恢复了体重下降,并显著改善了主要由水肿引起的脑重量增加。盐酸马尼地平改善了脑部的组织学变化。在联合用药组中,脑部和肾脏的组织学变化均得到改善。总之,与单独治疗相比,艾地苯醌和盐酸马尼地平联合使用显著改善了SHRSP脑卒中后的神经功能缺损以及脑部和肾脏的组织学变化。我们得出结论,盐酸马尼地平增强了艾地苯醌在治疗脑血管疾病中的治疗效果。